Mesenteric Artery IschemiaAMIGONCT07274306
Incidence, Treatment and Outcome After Acute Mesenteric Ischemia in the Region of Västra Götaland, 2000-2023.
An observational study of Mesenteric Artery Ischemia, run by Sahlgrenska University Hospital at 2 sites in Sweden.
Trial summary
The goal of this retrospective observational study is to describe the incidence and outcome of patients diagnosed with acute mesenteric ischemia (AMI) in the Västra Götaland region of Sweden between 2000-2023. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Mesenteric Artery Ischemia
- How many people
- 2,446 participants
- Where
- 2 sitesSweden
- Study dates
- 24 Feb 2025to Jan 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Adult, Older adult
Study population: Inhabitants of the Västra Götaland region in Sweden.
Who may be able to join
- all patients discharged from hospital with acute mesenteric ischemia (ICD K55.0 and K55.9)
Who cannot join
- -
Trial locations and contacts
2 sites in 1 country.
Sweden2 sites
Sahlgrenska hospital/Östra hospital
Gothenburg, Västra Götaland County, 41685
Sahlgrenska University Hospital
Gothenburg
About this study
Official title: Incidence, Treatment of and Outcome of Acute Mesenteric Ischemia in the Region of Västra Götaland, 2000-2023 - a Retrospective Observational Study
The goal of this retrospective observational study is to describe the incidence and outcome of patients diagnosed with acute mesenteric ischemia (AMI) in the Västra Götaland region of Sweden between 2000-2023. The main questions it aims to answer are:
- What was the observed incidence and outcome, and how did it change during the time period?
- How did socioeconomic factors influence incidence and outcome of AMI?
- What main surgical approaches were selected for these patients?
- What was the distribution of anticoagulant use in the cohort, and what effect did the introduction of new oral anticoagulants (NOAC) have on incidence and mortality in AMI?
- What was the prevalence of Short Bowel Syndrome (SBS) after surgical intervention?
Participants were obtained from the regional diagnosis registry. Additional datapoints were obtained from the Swedish statistics bureau and pharmaceutical registers.
- Conditions
- Mesenteric Artery Ischemia
- Keywords
- Acute mesenteric ischemia, Mesenteric ischemia, Intestinal ischemia, Population-based cohort, Epidemiology, Incidence, Mortality, Mesenteric arterial occlusion, Sweden / Västra Götaland
- Medical subject headings
- Mesenteric Ischemia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| VG Region patients with AMI diagnosis 2000-2023 | A cohort of all patients who were discharged with the diagnosis acute mesenteric ischemia (ICD-10: K55.0 or K55.9) in the Västra Götaland region of Sweden between 2000-01-01 and 2023-12-31. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Incidence of acute mesenteric ischemia
Annual incidence rate of acute mesenteric ischemia per 100,000 person-years in the Västra Götaland region.
Measured: Year 2000-2023
Mortality from acute mesenteric ischemia
All-cause mortality within up to 1 year of AMI diagnosis.
Measured: 30 days, 90 days, 1 year.
Secondary outcomes (5)
Temporal trends in incidence and mortality
Change over time in incidence and mortality, including before and after introduction of non-vitamin K antagonist oral anticoagulants (NOACs).
Measured: Year 2000-2023
Socioeconomic determinants of incidence and outcome
Association between SES indicators (income, education, immigration status, geographic distance to care) and risk of AMI or mortality.
Measured: Year 2000-2023
Surgical management strategy
Proportion of patients undergoing bowel resection, revascularization (open or endovascular), or non-operative management.
Measured: Year 2000-2023
Prevalence of Short Bowel Syndrome (SBS)
Number and percentage of patients developing SBS (ICD-10 K91.2 and K90.8) after AMI.
Measured: Within 1 year of surgical intervention
Anticoagulant use patterns
Proportion of patients using vitamin-K antagonists, NOACs, antiplatelet therapy, or no anticoagulation; association with incidence and survival.
Measured: At AMI diagnosis; trends from 2000-2023
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Dec 2025
- Study start24 Feb 2025
- Primary completionDec 2025 (estimated)
- Study completionJan 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Mesenteric Artery IschemiaStudies of the same condition, open and under way.
- More trials run by Sahlgrenska University HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 2,446 participants (actual)
Sponsor and investigators
- Lead sponsor
- Sahlgrenska University Hospital
- Sponsor type
- University, hospital or other
- Collaborators
- Gothia Forum - Center for Clinical Trial, Göteborg University
- Responsible party
- Principal investigator, Hanna de la Croix, Sahlgrenska University Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07274306
- Sponsor's protocol ID
- 2024-04585-01
- Acronym
- AMIGO
- Status last verified
- Nov 2025
- First submitted
- 27 Nov 2025
- Last updated
- 10 Dec 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Individual participant data will not be shared. Due to Swedish data protection legislation and ethical restrictions, the de-identified dataset cannot be made publicly available. Only aggregated results will be published.
Study at a glance
From the registry record, last updated by the sponsor on 10 Dec 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Incidence, Treatment of and Outcome of Acute Mesenteric Ischemia in the Region of Västra Götaland, 2000-2023 - a Retrospective Observational Study
- ClinicalTrials.gov ID
- NCT07274306
- Acronym / sponsor ID
- AMIGO / 2024-04585-01
- Conditions
- Mesenteric Artery Ischemia
- Keywords
- Acute mesenteric ischemia, Mesenteric ischemia, Intestinal ischemia, Population-based cohort, Epidemiology, Incidence, Mortality, Mesenteric arterial occlusion
- Study type
- Observational
- Recruitment status
- Active, not recruiting
- Enrolment
- 2,446 participants (actual)
- Lead sponsor
- Sahlgrenska University HospitalUniversity, hospital or other
- Collaborators
- Gothia Forum - Center for Clinical Trial, Göteborg University
- Study start
- 24 Feb 2025 (actual)
- Primary completion
- Dec 2025 (estimated)
- Study completion
- Jan 2026 (estimated)
- First posted
- 10 Dec 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this retrospective observational study is to describe the incidence and outcome of patients diagnosed with acute mesenteric ischemia (AMI) in the Västra Götaland region of Sweden between 2000-2023. The main questions it aims to answer are:
- What was the observed incidence and outcome, and how did it change during the time period?
- How did socioeconomic factors influence incidence and outcome of AMI?
- What main surgical approaches were selected for these patients?
- What was the distribution of anticoagulant use in the cohort, and what effect did the introduction of new oral anticoagulants (NOAC) have on incidence and mortality in AMI?
- What was the prevalence of Short Bowel Syndrome (SBS) after surgical intervention?
Participants were obtained from the regional diagnosis registry. Additional datapoints were obtained from the Swedish statistics bureau and pharmaceutical registers.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| VG Region patients with AMI diagnosis 2000-2023 | – | –A cohort of all patients who were discharged with the diagnosis acute mesenteric ischemia (ICD-10: K55.0 or K55.9) in the Västra Götaland region of Sweden between 2000-01-01 and 2023-12-31. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Age groups
- Adult, Older adult
- Study population
- Inhabitants of the Västra Götaland region in Sweden.
Key inclusion criteria (1 listed)
- all patients discharged from hospital with acute mesenteric ischemia (ICD K55.0 and K55.9)
Key exclusion criteria (1 listed)
- -
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Incidence of acute mesenteric ischemia
Time frame: Year 2000-2023
Annual incidence rate of acute mesenteric ischemia per 100,000 person-years in the Västra Götaland region.
Mortality from acute mesenteric ischemia
Time frame: 30 days, 90 days, 1 year.
All-cause mortality within up to 1 year of AMI diagnosis.
5 secondary outcomes
Temporal trends in incidence and mortality
Time frame: Year 2000-2023
Socioeconomic determinants of incidence and outcome
Time frame: Year 2000-2023
Surgical management strategy
Time frame: Year 2000-2023
Prevalence of Short Bowel Syndrome (SBS)
Time frame: Within 1 year of surgical intervention
Anticoagulant use patterns
Time frame: At AMI diagnosis; trends from 2000-2023
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Dec 2025.
- Individual participant dataSharing planned: No. Individual participant data will not be shared. Due to Swedish data protection legislation and ethical restrictions, the de-identified dataset cannot be made publicly available. Only aggregated results will be published.
Related trials for Mesenteric Artery Ischemia
Recruiting
Mesenteric Ischemia Markers Study
Mesenteric Vascular Disease
Active, not recruiting
ThromBus Aspiration for Acute Mesenteric Artery Occlusion With Emergent Laparoscopic Surgery
Acute Mesenteric Ischemia
Recruiting
Coeliac Artery Release or Sham Operation
Mesenteric Ischemia, Median Arcuate Ligament Syndrome
Recruiting
Safety & Efficacy of Ischemic Preconditioning by Embolization of the Inferior Mesenteric Artery in Surgery for Tumors of Lower and Middle Rectum
Cancer, Rectal
RecruitingObservational study
Translesional PRESSURE Measurements to Assess Clinical Relevance of a Mesenteric Artery Stenosis (PRESSURE-study)
Chronic Mesenteric Ischemia, Ischemia, Mesenteric
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Mesenteric Artery Ischemia, run by Sahlgrenska University Hospital at 2 sites in Sweden.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 10 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in Sweden. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Incidence of acute mesenteric ischemia (time frame: Year 2000-2023). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Dec 2025.